These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 34294629)

  • 1. Effects of dopaminergic treatment on inhibitory control differ across Hoehn and Yahr stages of Parkinson's disease.
    Mirabella G; Pilotto A; Rizzardi A; Montalti M; Olivola E; Zatti C; Di Caprio V; Ferrari E; Modugno N; Padovani A
    Brain Commun; 2024; 6(1):fcad350. PubMed ID: 38162902
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Focus on Depression in Parkinson's Disease: A Delphi Consensus of Experts in Psychiatry, Neurology, and Geriatrics.
    Agüera-Ortiz L; García-Ramos R; Grandas Pérez FJ; López-Álvarez J; Montes Rodríguez JM; Olazarán Rodríguez FJ; Olivera Pueyo J; Pelegrín Valero C; Porta-Etessam J
    Parkinsons Dis; 2021; 2021():6621991. PubMed ID: 33628415
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early onset Parkinson's disease in the cycle of 3,4-methylenedioxymethamphetamine and substance use: a case report.
    Hui T; Guo S
    J Med Case Rep; 2023 Sep; 17(1):405. PubMed ID: 37740189
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Case report: Dopamine Dysregulation Syndrome, mania, and compulsive buying in a patient with Parkinson's disease.
    Silva C; Rebelo M; Chendo I
    Front Neurol; 2023; 14():1290653. PubMed ID: 38053797
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Idiopathic Parkinson's Disease and Schizophrenia: Dilemma in Diagnosis and Treatment of a Case.
    Sharma S; Aggarwal N
    Iran J Psychiatry; 2019 Apr; 14(2):179-181. PubMed ID: 31440300
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-Pharmacological Interventions for Depression and Anxiety in Parkinson's Disease.
    van Wegen EEH; van Balkom TD; Hirsch MA; Rutten S; van den Heuvel OA
    J Parkinsons Dis; 2024 Apr; ():. PubMed ID: 38607762
    [No Abstract]   [Full Text] [Related]  

  • 7. Clinical features of drug-induced Parkinsonism.
    Shiraiwa N; Tamaoka A; Ohkoshi N
    Neurol Int; 2018 Dec; 10(4):7877. PubMed ID: 30687468
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Parkinsonism-hyperpyrexia, a rare consequence of deep brain stimulator malfunction in advanced Parkinson's disease.
    Díaz Castela M; Prendes Fernández P; Heres Bruck S; Suárez San Martín E; García Fernández C; Sol Álvarez J; Lozano Aragoneses B; Sáiz Ayala A; Santamarta Liébana E; Álvarez Carriles J; González Álvarez L; Blázquez Estrada M
    Clin Park Relat Disord; 2024; 10():100246. PubMed ID: 38444738
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Editorial: Early diagnosis and mechanism analysis of non-motor symptoms of Parkinson's syndrome.
    Yuan M; Xu Q; Han M; Pan H
    Front Neurol; 2024; 15():1434924. PubMed ID: 38933325
    [No Abstract]   [Full Text] [Related]  

  • 10. Brain-penetrating neurotrophic factor mimetics: HER-096 as a disease-modifying therapy for Parkinson's disease.
    Kulesskaya N; Holmström KM; Huttunen HJ
    Neural Regen Res; 2025 Apr; 20(4):1094-1095. PubMed ID: 38989947
    [No Abstract]   [Full Text] [Related]  

  • 11. Is the risk of Parkinson's syndrome reducible?
    Wenderlein JM
    Dtsch Arztebl Int; 2008 Jan; 105(3):54; author reply 54. PubMed ID: 19633756
    [No Abstract]   [Full Text] [Related]  

  • 12. Treatment of Malignant Disease.
    Med Exam (Phila); 1844 Mar; 7(5):60. PubMed ID: 38122316
    [No Abstract]   [Full Text] [Related]  

  • 13. Efficacy of Electroconvulsive Therapy for the Treatment of Movement Disorders: A Literature Review.
    Muhammad N; Brooks Iii N; Chatham L; Chatham A; Muthukanagaraj P
    Cureus; 2023 Mar; 15(3):e36634. PubMed ID: 36968685
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Parkinsonism-Hyperpyrexia Syndrome and Dyskinesia-Hyperpyrexia Syndrome in Parkinson's Disease: Two Cases and Literature Review.
    Wang JY; Huang JF; Zhu SG; Huang SS; Liu RP; Hu BL; Zhu JH; Zhang X
    J Parkinsons Dis; 2022; 12(6):1727-1735. PubMed ID: 35811538
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Electroconvulsive Therapy for Parkinson's Disease with Depression and Neuroleptic Malignant Syndrome: A Case Report.
    Mori Y; Miura I; Nozaki M; Osakabe Y; Izumi R; Akama T; Kimura S; Yabe H
    Clin Psychopharmacol Neurosci; 2021 Aug; 19(3):572-575. PubMed ID: 34294629
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [A case of Parkinson's disease with neuroleptic malignant syndrome induced by paroxetine].
    Hamada Y; Miyamoto K; Inatsugi Y; Suzuki H; Kusunoki S
    Rinsho Shinkeigaku; 2006 Aug; 46(8):575-8. PubMed ID: 17154040
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neuroleptic malignant syndrome: a case responding to electroconvulsive therapy plus bupropion.
    Foguet-Boreu Q; Coll-Negre M; Serra-Millàs M; Cavalleria-Verdaguer M
    Clin Pract; 2018 Jan; 8(1):1044. PubMed ID: 29441189
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [A-56-year-old woman with parkinsonism, whose mother had Parkinson's disease].
    Shimo Y; Takanashi M; Ohta S; Terashima K; Mori H; Shirai T; Miwa H; Mizuno Y
    No To Shinkei; 2001 May; 53(5):495-505. PubMed ID: 11428377
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Electroconvulsive therapy in Parkinson's disease.
    Calderón-Fajardo H; Cervantes-Arriaga A; Llorens-Arenas R; Ramírez-Bermudez J; Ruiz-Chow Á; Rodríguez-Violante M
    Arq Neuropsiquiatr; 2015 Oct; 73(10):856-60. PubMed ID: 26331387
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.